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881to be the most frequently reported complication (1–4),
whereas stroke and pump thrombosis are among the most
serious.
The HeartMate II (HMII) CF-LVAD (Thoratec Cor-
poration, Pleasanton, California) is approved by the U.S.
Food and Drug Administration for both bridge to trans-
plantation (BTT) and destination therapy (DT) for long-
term support. The HMII destination therapy trial was a
prospective, randomized study comparing the HMII CF-
LVAD with the HeartMate XVE pulsatile-ﬂow left ven-
tricular assist device (LVAD) (Thoratec Corporation) (1).
Bleeding was high in both the CF-LVAD and pulsatile
LVAD cohorts, with >75% of the patients requiring trans-
fusions post-LVAD surgery, and there was a trend toward a
lower incidence of bleeding in the HMII cohort. The inci-
dence of ischemic stroke (0.06 events per patient-year [EPPY]
vs. 0.10 EPPY) and hemorrhagic stroke (0.07 EPPY vs. 0.12
EPPY) was not statistically different between the HMII and
HeartMate XVE. More recent data from additional DT trial
patients have shown a reduction in hemorrhagic stroke (from
0.07 to 0.03 EPPY) and in bleeding (from 1.66 to 1.13
EPPY) (4). Recent results from INTERMACS (Interagency
Registry for Mechanically Assisted Circulatory Support) for
1,496 BTT patients have also suggested some improvements,
with a combined occurrence of ischemic and hemorrhagic
stroke at 8% and gastrointestinal bleeding at 10% (5).
The causes of bleeding are multifactorial, but recent
studies have shown that von Willebrand syndrome has
developed in patients with CF-LVADs because of a loss in
high-molecular-weight von Willebrand factor multimers,
which results in reduced platelet activity and aggregation
(6–10). Additionally, along with aspirin, HMII patients are
also typically anticoagulated with warfarin, with a target in-
ternational normalized ratio range of 1.5 to 2.5 in the absence
of an additional indication for warfarin (11,12). Single-center
studies have identiﬁed age, ischemic cardiomyopathy,
hypertension, body mass index (BMI), albumin, cardiopul-
monary bypass time, and history of gastrointestinal bleeding
as pre-operative risk factors for bleeding post-LVAD
implantation (8,13–15).
Compared with bleeding, the risks of stroke and pump
thrombosis with the HMII have been shown to be low, both
in single-center and multicenter experiences (11,16,17).
However, these are among the most serious events that
deserve continued attention for improvements. There are
only a few published reports evaluating risk factors for stroke
and thrombosis in CF-LVAD patients because single-center
studies lack the power necessary to identify statistically
signiﬁcant factors when the frequency of events is low.
Previous single-center studies have identiﬁed history of ce-
rebrovascular accident, serum sodium, and serum albumin
(18) and right atrial pressure and right ventricular end-
diastolic dimension (19) as pre-operative risk factors for
post-LVAD ischemic and hemorrhagic stroke.
The primary purpose of this study was to determine pre-
operative risk factors related to post-discharge bleeding,stroke, and pump thrombosis
in both BTT and DT HMII
LVAD patients in the multi-
center clinical trials. Because the
perioperative period is associated
with highly confounding factors
related to surgery and post-
operative recovery, which will be
addressed in separate analyses,
we elected to solely focus this
study on the events that occurred
after patients were discharged
from the hospital and were being
managed as outpatients.Methods
Study design. This study was a retrospective analysis of
patients implanted with the HMII as part of the BTT and
DT clinical trials. Details of the study design and trial results
for BTT and DT were previously published (1,2). Between
March 2005 and January 2010, 1,302 patients were enrolled
in the study, including the continued access protocol phase,
and received the HMII device as BTT, DT, compassionate
use, or an exchange for a failing, previously implanted
HeartMate XVE. For this study, HeartMate XVE ex-
change (n ¼ 140) and compassionate use (n ¼ 33) patients
were excluded. As of March 6, 2012, all patients had at least
2 years of follow-up. Of the remaining 1,129 patients, a total
of 956 patients were successfully discharged; they form the
subjects of the present analysis. All adverse events were
tracked and adjudicated by an independent clinical events
committee. Bleeding, hemorrhagic and ischemic stroke, and
pump thrombosis were the primary adverse events that were
investigated in this study. Laboratory and hemodynamic
measurements were collected every month until outcome or
for up to 6 months for BTT patients and 24 months for DT
patients.
Adverse event deﬁnitions. Bleeding was deﬁned as an
episode of internal or external bleeding that resulted in
death, reoperation, or permanent injury or necessitated the
transfusion of 2 U of packed red blood cells within 24 h of
the event. Each bleeding event was categorized based on
its location or cause into: 1) gastrointestinal bleeding;
2) epistaxis; 3) anemia; 4) wound; 5) other; 6) no site
identiﬁed; or 7) no site reported. A stroke event was deﬁned
as a neurological deﬁcit lasting >24 h or 24 h with a brain
imaging study showing new infarction. Each stroke was
categorized as either hemorrhagic or ischemic by the study
center, which was subsequently conﬁrmed by the clinical
events committee. Pump thrombosis was deﬁned as an
obstructive thrombus in the device or its conduits associated
with clinical symptoms of impaired pump performance
(e.g., decreased pump ﬂow, need to increase pump speed,
increased power, or hemolysis) or the need for thrombolytic
or surgical intervention. Deﬁnitions of all other adverse
Table 1
Baseline Demographics of Patients Evaluated in This
Study (N ¼ 956) and Duration of LVAD Support
Characteristic
Sex
Male 736 (77)
Female 220 (23)
Indication
BTT 405 (42)
DT 551 (58)
Age (range), yrs 58.2  14.0 (15–87)
Ischemic etiology 506 (53)
African American 187 (20)
Body surface area 1.97  0.27
BMI, kg/m2 27.1  5.8
LVEF, % 16.7  6.0
LVEDD, mm 69.2  11.1
ACE inhibitors 281 (29)
ARBs 66 (7)
Beta-blockers 429 (45)
Cardiac resynchronization therapy 534 (56)
Intravenous inotropes 781 (82)
Intra-aortic balloon pump 266 (28)
Duration of support 1.5 yrs (15 days, 6.8 yrs)
Duration of support post-discharge 1.4 (1 day, 6.8 yrs)
Pre-operative laboratory/hematology results
BUN, mg/dl 31.7  19.9
Creatinine, mg/dl 1.44  0.53
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BTT (2) and DT (1) publications.
Statistical analysis. Continuous variables are described
as mean  SD or median (range) as appropriate, and
categorical variables are described in percentages. Adverse
events are presented as the percentage of patients affected,
and event rates as EPPY. Statistical signiﬁcance was set
at p < 0.05 unless explicitly stated otherwise. Univariable
and multivariable associations of each adverse event with
pre-operative factors were evaluated using Cox propor-
tional hazards models because of variability in support
durations across different cohorts (e.g., BTT vs. DT,
males vs. females). Patients were censored if they under-
went transplantation, died, or had their devices explanted
for myocardial recovery. Variables with signiﬁcant associ-
ations as deﬁned by p < 0.1 on univariate analysis were
entered into a multivariable model. Variables were
included in a stepwise fashion and retained if the p value
was <0.05 in the multivariable model. Care was taken to
not overﬁt the model and to limit the number of variables
entered into the multivariable model to <10 per event.
In certain cases, continuous variables were dichotomized
based on upper or lower quartiles, except for age, which
was dichotomized to 65 years of age and older. Statistical
analyses were performed using SAS version 9.2 (SAS
Institute, Cary, North Carolina).Total bilirubin, mg/dl 1.22  0.85
ALT, U/l 64  163
AST, U/l 55  143
INR 1.33  0.57
PTT, s 25.6  2.6
Hemoglobin, g/dl 11.6  1.96
Hematocrit, % 35.1  5.6
WBC count, 1,000/mm3 8.2  3.1
Platelet count, 1,000/mm3 217  86
Values are n (%), mean  SD, or median (minimum, maximum), unless otherwise indicated.
ACE ¼ angiotensin-converting enzyme; ALT ¼ alanine aminotransferase; ARB ¼ angiotensin
receptor blocker; AST ¼ aspartate aminotransferase; BMI ¼ body mass index; BTT ¼ bridge to
transplantation; BUN ¼ blood urea nitrogen; DT ¼ destination therapy; INR ¼ international
normalized ratio; LVEDD ¼ left ventricular end-diastolic diameter; LVEF ¼ left ventricular ejection
fraction; PTT ¼ partial thromboplastin time; WBC ¼ white blood cell.Results
Baseline characteristics. Baseline characteristics of patients
are shown in Table 1. A total of 956 patients were included
and successfully discharged from the hospital. Median time
to discharge was 24 days, and patients were supported for a
median of 1.5 years for an accumulated duration of 1,799
patient-years, with 1,715 patient-years spent post-initial
discharge. The average age was 58.2  14.0 years, 23%
were women, and 42% of the patients were BTT. Before
surgery, 82% of the patients were on intravenous inotropes,
56% had cardiac resynchronization therapy devices, and 28%
were supported on an intra-aortic balloon pump. Overall,
the patient demographics matched the other patient cohorts
whose outcomes were described in previous BTT and DT
trials (1–4).
Prevalence and incidence of bleeding, hemorrhagic
stroke, and pump thrombosis. The incidence of post-
discharge bleeding, hemorrhagic stroke, ischemic stroke,
and pump thrombosis is shown in Table 2. The overall
prevalence and incidence of bleeding requiring transfusion
were 38% (0.65 EPPY), with a greater incidence of bleeding
in DT patients (47%, 0.72 EPPY) compared with BTT
patients (25%, 0.48 EPPY) (p ¼ 0.001). DT patients also
had a higher incidence of gastrointestinal bleeding (29%,
0.35 EPPY) compared with BTT patients (13%, 0.19
EPPY) (p < 0.001). The majority of bleeding events re-
sulting in transfusion were from the gastrointestinal tract
(45%), followed by wound site (12%) and epistaxis (4%).Anemia was the reason for transfusion in 14% of patients. No
speciﬁc site could be identiﬁed in 15% of the patients, and in
5% of the patients, the sites of bleeding were not reported.
The overall prevalence of hemorrhagic stroke was 8% of
patients, with an incidence rate of 0.05 EPPY, and there was
no difference between BTT (6%, 0.05 EPPY) and DT (9%,
0.04 EPPY) patients (p ¼ 0.734). Ischemic stroke occurred
in 6% of the patients (0.04 EPPY), with no statistically
signiﬁcant difference between the BTT (4%, 0.03 EPPY)
and DT (8%, 0.04 EPPY) patients (p ¼ 0.386). Clinically
relevant pump thrombosis was reported in 4% of the pati-
ents (0.03 EPPY), with a trend toward higher prevalence
in DT patients (6%, 0.03 EPPY) compared with BTT
patients (2%, 0.01 EPPY) (p ¼ 0.086).
Fifty-eight patients (6%) experienced both hemorrhagic
(bleeding or hemorrhagic stroke) and ischemic events
Table 2 Prevalence and Incidence of Bleeding, Stroke, and Pump Thrombosis After Discharge
Event
Patients, n (%) Events (Event per Patient-Year)
All Patients
(N ¼ 956)
BTT
(n ¼ 405)
DT
(n ¼ 551)
All Patients
(1,715 pt-yrs)
BTT
(523 pt-yrs)
DT
(1,192 pt-yrs)
Hemorrhagic events
Bleeding requiring surgery 33 (3) 12 (3) 21 (4) 35 (0.02) 12 (0.03) 23 (0.02)
Bleeding requiring 2 U PRBCs 361 (38) 103 (25) 258 (47) 1,108 (0.65) 253 (0.48) 855 (0.72)
GI bleeding 213 (22) 52 (13) 161 (29) 518 (0.30) 101 (0.19) 417 (0.35)
Hemorrhagic stroke 76 (8) 25 (6) 51 (9) 80 (0.05) 27 (0.05) 53 (0.04)
Thrombotic events
Ischemic stroke 58 (6) 15 (4) 43 (8) 61 (0.04) 16 (0.03) 45 (0.04)
Pump thrombosis 38 (4) 7 (2) 31 (6) 43 (0.03) 7 (0.01) 36 (0.03)
GI ¼ gastrointestinal; PRBCs ¼ packed red blood cells; pt-yrs ¼ patient-years; other abbreviations as in Table 1.
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883(ischemic stroke or pump thrombosis). A total of 36 patients
experienced an ischemic event after a hemorrhagic event at
an average of 316 days after the initial hemorrhagic event;
10 of these 36 patients experienced the ischemic event
within 90 days of the hemorrhagic event. It is certainly
possible that a patient with a hemorrhagic event could be at a
higher risk of an ischemic event later on if anticoagulation is
withheld. However, details pertaining to the intervention for
a hemorrhagic event were not captured in this study. Hence,
it is difﬁcult to say whether the ischemic event was an iso-
lated event or due to a management response to treat a
hemorrhagic event.Table 3
Pre-Operative Statistically Signiﬁcant Univariable Correlates
Post-Discharge Bleeding
Parameter
Univariable
No
(n ¼ 584)
Yes
(n ¼ 372)
DT (n ¼ 551) 287 (52) 264 (48)
BTT (n ¼ 405) 297 (73) 108 (27)
Age, yrs 56  15 61  13
>65 (n ¼ 340) 169 (50) 171 (50)
65 (n ¼ 616) 415 (67) 201 (33)
Female (n ¼ 220) 117 (53) 103 (47)
Male (n ¼ 736) 467 (63) 269 (37)
Ischemic cardiomyopathy (n ¼ 506) 291 (58) 215 (42)
Nonischemic cardiomyopathy (n ¼ 450) 293 (65) 157 (35)
Diabetes (n ¼ 345) 177 (51) 168 (49)
No diabetes (n ¼ 611) 407 (67) 204 (33)
Bypass time, min 99  40 109  56
BMI, kg/m2 26.7  5.7 27.7  5.9
LVEDD, mm 70.0  11.0 67.9  11.0
CVP, mm Hg 12.2  6.6 12.9  6.2
CI, l/min/m2 1.98  0.62 2.07  0.65
Diastolic BP 63  12 61  12
Albumin, g/dl 3.50  0.59 3.44  0.55
HCT 35.6  5.8 34.4  5.3
>31% (n ¼ 708) 450 (64) 258 (36)
31% (n ¼ 243) 130 (54) 113 (46)
Hemoglobin, g/dl 11.8  2.0 11.4  1.8
Values are n (%) or mean  SD. *Hazard ratio (HR): >65 years of age compared with 65 years of ag
BP ¼ blood pressure; CI ¼ cardiac index; CVP ¼ central venous pressure; HCT ¼ hematocrit; other abPre-operative risk factors of bleeding, stroke, and pump
thrombosis. The statistically signiﬁcant pre-operative
clinical characteristics of patients related to bleeding,
stroke, and pump thrombosis are shown in Tables 3, 4, 5,
and 6. DT, older age, female, ischemic etiology, higher
BMI, lower left ventricular end-diastolic diameter, higher
cardiac index, higher blood urea nitrogen, lower hematocrit,
history of diabetes, and lower hemoglobin correlated with
bleeding post-discharge. When included in a multivariable
model, the independent risk factors for bleeding were >65
years of age, sex, ischemic etiology, and lowest quartile he-
matocrit (31%) (Table 3, Fig. 1).(p < 0.1) and Multivariable Risk Factors for
Post-Discharge Bleeding
Correlates Multivariable Risk Factors
p Value
(Cox)
HR (95% CI)
(Cox)
p Value
(Cox)
HR (95% CI)
(Cox)
0.001 1.44 (1.15–1.81) d d
<0.001 1.02 (1.01–1.02)
0.015
1.31 (1.05–1.62)*
0.006 1.33 (1.09–1.64)*
0.013 1.33 (1.06–1.67) 0.022 1.45 (1.14–1.84)
0.01 1.31 (1.07–1.61) 0.008 1.35 (1.08–1.69)
<0.001 1.71 (1.391–2.09) d d
0.003 1.003 (1.001–1.005) d d
0.041 1.02 (1.00–1.03) d d
0.005 0.99 (0.98–1.00) d d
0.083 1.01 (1.00–1.03) d d
0.008 1.24 (1.06–1.44) d d
0.004 0.99 (0.98–1.00) d d
0.080 0.86 (0.72–1.02) d d
<0.001 0.97 (0.95–0.98) d d
0.003 1.41 (1.13–1.75) 0.023 1.31 (1.04–1.64)
<0.001 0.91 (0.86–0.96) d d
e.
breviations as in Table 1.
Table 4
Pre-Operative Statistically Signiﬁcant Univariable Correlates (p < 0.1) and Multivariable Risk Factors for
Post-Discharge Hemorrhagic Stroke
Parameter
Post-Discharge Hemorrhagic Stroke
Univariable Correlates Multivariable Risk Factors
No
(n ¼ 880)
Yes
(n ¼ 76)
p Value
(Cox)
HR (95% CI)
(Cox)
p Value
(Cox)
HR (95% CI)
(Cox)
Age, yrs 58  14 59  11 0.688 d d d
>65 (n ¼ 340) 319 (94) 21 (6) 0.003 2.13 (1.30–3.57)* 0.010 1.94 (1.17–3.23)*
65 (n ¼ 616) 561 (91) 55 (9)
Sex
Female (n ¼ 220) 189 (86) 31 (14) 0.001 2.14 (1.35–3.38) 0.006 1.92 (1.21–3.05)
Male (n ¼ 736) 691 (94) 45 (6)
Pre-albumin, mg/dl 18.6  7.2 20.0  8.2 0.038 1.03 (1.00–1.07) d d
Inotropes
Yes (n ¼ 781) 714 (91) 67 (9) 0.085 1.84 (0.92–3.70) d d
No (n ¼ 175) 166 (95) 9 (5)
Values are n (%) and mean  SD. *Hazard ratio (HR): 65 years of age compared with >65 years of age.
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strokes were age 65 years, female, and serum pre-albumin
(Table 4). Additionally, patients on inotropes before LVAD
implantation had a trend toward a higher incidence of
hemorrhagic stroke (p ¼ 0.085). On multivariable analysis,
the variables found to be statistically signiﬁcant were
age 65 years and female (Table 4, Fig. 2).
There were trends toward higher ischemic stroke rates in
patients with a higher platelet count, lower baseline inter-
national normalized ratio, lower partial thromboplastin time,
history of diabetes, and lower Model for End-Stage Liver
Disease score. On multivariable analysis, the independent
risk factors for ischemic stroke were female and history of
diabetes (Table 5, Fig. 1).
A similar analysis was performed to identify correlates of
pump thrombosis. Higher BMI, pulmonary capillary wedgeTable 5
Pre-Operative Statistically Signiﬁcant Univariable Correlates
Post-Discharge Ischemic Stroke
Parameter
Po
Univariable Correlates
No
(n ¼ 898)
Yes
(n ¼ 58)
p Valu
(Cox
Sex
Female (n ¼ 220) 199 (90) 21 (10) 0.02
Male (n ¼ 736) 699 (95) 37 (5)
BMI, kg/m2 27.0  5.8 28.7  6.6 0.03
BUN, mg/dl 32.3  20.2 23.5  13.1 <0.00
TBILI, mg/dl 1.23  0.85 1.03  0.74 0.06
PLT, 1,000/mm3 216  87 235  82 0.05
Diabetes
Yes (n ¼ 345) 315 (91) 30 (9) 0.01
No (n ¼ 611) 583 (95) 28 (5)
Baseline INR 1.34  0.58 1.21  0.24 0.05
Baseline PTT 45.5  26.1 38.5  14.5 0.07
Baseline MELD 13.4  4.7 11.7  3.4 0.01
Values shown are n (%) and mean  SD.
MELD ¼ Model for End-Stage Liver Disease; PLT ¼ platelets; TBILI ¼ total bilirubin; other abbreviationpressure, and white blood count were found to be statistically
signiﬁcant factors. However, there were trends toward a
higher incidence of pump thrombosis in DT patients, female
patients, and those with a nonischemic etiology. On
multivariable analysis, the only statistically signiﬁcant inde-
pendent factor was BMI (p ¼ 0.031), with a trend toward
signiﬁcance for female (p ¼ 0.057).
Impact of age and sex on bleeding, hemorrhagic stroke,
ischemic stroke, and pump thrombosis. Figure 2 shows
the adverse event rates for bleeding, hemorrhagic stroke,
ischemic stroke, and pump thrombosis stratiﬁed by age
(65 and >65 years) and sex. Men who were 65 years of
age had the lowest incidence of post-discharge bleeding
events, whereas women >65 years of age had the highest
incidence of bleeding. Men >65 years of age had a higher
incidence of bleeding compared with men 65 years of age,(p < 0.1) and Multivariable Risk Factors for
st-Discharge Ischemic Stroke
Multivariable Risk Factors
e
)
HR (95% CI)
(Cox)
p Value
(Cox)
HR (95% CI)
(Cox)
8 1.82 (1.07–3.11) 0.021 1.88 (1.10–3.34)
3 1.56 (1.04–2.33)
per 10 U
d d
1 0.964 (0.94–0.99) d d
8 0.67 (0.44–1.03) d d
4 1.00 ( 1.00–1.01) d d
1 1.95 (1.16–3.26) 0.009 1.99 (1.19–3.34)
7 0.30 (0.09–1.03) d d
6 0.99 (0.97–1.00) d d
9 0.93 (0.87–0.99) d d
s as in Table 1.
Table 6 Pre-Operative Univariable Correlates With p < 0.1 and Multivariable Risk Factors for Post-Discharge Pump Thrombosis
Parameter
Post-Discharge Pump Thrombosis
Univariable Correlates Multivariable Risk Factors
No
(n ¼ 918)
Yes
(n ¼ 38)
p Value
(Cox)
HR (95% CI)
(Cox)
p Value
(Cox)
HR (95% CI)
(Cox)
DT (n ¼ 551) 520 (94) 31 (6) 0.086 2.06 (0.90–4.71) d d
BTT (n ¼ 405) 398 (98) 7 (2) d d
Age, yrs 58  14 56  14 0.087 0.98 (0.96–1.00) d d
>65 (n ¼ 340) 329 (96.8) 11 (3.2) 0.062 0.511 (0.25–1.033) d d
65 (n ¼ 616) 589 (95.6) 27 (4.4) d d
Sex
Female (n ¼ 220) 206 (94) 14 (6) 0.060 1.86 (0.96–3.59) 0.057 1.90 (0.98–3.67)
Male (n ¼ 736) 712 (97) 24 (3)
Ischemic cardiomyopathy (n ¼ 506) 491 (97) 15 (3) 0.074 0.55 (0.29–1.06) d d
Nonischemic cardiomyopathy (n ¼ 450) 427 (95) 23 (5) d d
BMI, kg/m2 27.0  5.8 29.1  5.6 0.037 1.69 (1.03–2.77) 0.031 1.71 (1.5–2.77)
per 10 U
Pulmonary capillary wedge pressure, mm Hg 24.6  8.4 27.6  7.1 0.027 1.05 (1.01–1.09) d d
CVP, mm Hg 12.4  6.4 14.2  7.2 0.075 1.04 (1.00–1.09) d d
WBC count 8.1  3.1 8.9  3.2 0.046 1.09 (1.00–1.19) d d
Values are n (%) or mean  SD.
Abbreviations as in Tables 1 and 3.
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885but not higher than the incidence of bleeding in women
(both 65 and >65 years of age). By contrast, men >65
years of age had the lowest incidence of hemorrhagic strokes,
whereas women 65 years of age had the highest incidence
of post-discharge hemorrhagic strokes. Although men 65
years of age were at a higher risk compared with older men
for the development of hemorrhagic strokes, they were still
at a lower risk compared with younger women. Men >65
years of age had the lowest incidence rates for thrombo-
embolic events (ischemic stroke and pump thrombosis),
whereas women >65 years of age had the highest incidence
of thromboembolic events.Figure 1 Multivariable Risk Factors for Bleeding, Hemorrhagic Strok
Hazard ratios for severe thrombotic and hemorrhagic events. BMI ¼ body mass index; HDiscussion
This retrospective, multicenter analysis of 956 HMII
LVAD patients shows that the risk of post-discharge
bleeding, hemorrhagic stroke, ischemic stroke, and pump
thrombosis during LVAD support differs substantially in
subgroups of patients based on factors including sex, age,
body size, history of diabetes, and etiology of heart failure.
This study is the largest analysis of risk factors for hemor-
rhagic and thrombotic events in patients with LVADs.
Identiﬁcation of these risk factors may help in the devel-
opment of anticoagulation and antiplatelet strategiese, Ischemic Stroke, and Pump Thrombosis
CT ¼ hematocrit.
Figure 2 Impact of Age and Sex on Post-Discharge Bleeding, Hemorrhagic Stroke, Ischemic Stroke, and Pump Thrombosis
Event rates for men are shown in gray, and rates for women are shown in black.
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886appropriately targeted to minimize events in these
subgroups.
Clinical risk factors identiﬁed for post-discharge bleeding
events, 45% of which were gastrointestinal bleeding, include
older age, female, ischemic etiology, and a low pre-operative
hematocrit level. For hemorrhagic stroke, younger age and
female were signiﬁcant independent risk factors, whereas for
ischemic stroke, female and a history of diabetes were found to
be signiﬁcant factors. For pump thrombosis, female and
higher BMI were found to be the multivariable risk factors.
Female patients were found to be at risk of bleeding and
thrombotic adverse events. However, when stratiﬁed by age,
younger women (65 years of age) were at a higher risk of
hemorrhagic stroke,whereas olderwomenwere at a higher risk
of ischemic stroke.Therewere nodifferences between younger
and older women in the incidence of bleeding and pump
thrombosis, but both were higher compared with men.
Older age, and its associated risk of gastrointestinal
bleeding, was well documented in previous studies on
CF-LVADs (8,13–15). Our study also found that older
patients were at a higher risk of bleeding events, along
with ischemic etiology, female, and lower pre-operative
hematocrit. A lower hematocrit may be an indicator of
bleeding and anemia before LVAD surgery, and when
combined with acquired von Willebrand syndrome, which
has been shown to occur in patients with a CF-LVAD(6–9), along with the prescribed anticoagulation and anti-
platelet therapy, the risk of bleeding is increased.
We found a signiﬁcantly increased incidence of throm-
botic and hemorrhagic events in female patients compared
with male patients. An earlier univariable analysis performed
in the BTT cohort of patients from the same HMII trial by
Bogaev et al. (20) in 104 women and 361 men found a
higher hemorrhagic stroke rate (0.10 EPPY vs. 0.04 EPPY),
but similar rates of ischemic strokes and bleeding in women
versus men. Interestingly, despite the higher incidence of
hemorrhagic stroke, no differences in survival were found
between women and men, with women having a signiﬁcant
advantage over men in the incidence of other adverse events
such as sepsis and driveline infection. One could hypothesize
that the smaller size of women may be partly responsible for
the difference in events. However, in the current study, body
size area did not correlate with ischemic stroke or pump
thrombosis.
Women have been found to be at higher risk of some
acquired hypercoagulable states. The use of oral contracep-
tives or hormone replacement therapy has been associated
with an increased risk of venous thromboembolism (21,22).
The Framingham Heart Study found that women with
natural menopause before 42 years of age had twice the
ischemic stroke risk than those with a natural menopause
after the age of 42 years (23). The state of menopause and
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887details regarding the use of oral contraceptives or hormone
replacement therapy were unavailable, but these underlying
risk factors could be having an impact on the higher inci-
dence of ischemic strokes in older women and a higher
incidence of hemorrhagic strokes in younger women.
The ﬁndings of this study may help to identify a unique
patient proﬁle for appropriately targeting an anticoagulation
regimen to reduce the risk of bleeding. For example, an older
male patient with an ischemic etiology and low pre-operative
hematocrit may be able to tolerate and may be more appro-
priately managed on lower levels of anticoagulation compared
with a younger man. However, the goal of developing tar-
geted anticoagulation strategies speciﬁcally for female pa-
tients is complicated by the increased risk of hemorrhagic and
thrombotic events in females. Increasing anticoagulation or
antiplatelet therapy to reduce ischemic stroke could result in
a fatal hemorrhagic stroke. Initial targeted strategies for
subgroups should probably start with older male patients, in
whom the risk of ischemic stroke and pump thrombosis is
low, but the risk of bleeding is high. Further studies are
needed to identify whether prospectively targeting anti-
coagulation based on identiﬁed pre-operative risk factors
has an impact on the development of bleeding and throm-
boembolic events.
Study limitations. This was a retrospective analysis of pa-
tients in the pivotal clinical trial, which may not be repre-
sentative of patients in the population as a whole. Clearly,
bias and confounding effects can be introduced because
there was no randomization or blinding. Therefore, caution
should be used in interpreting the results of this study. Also,
because the objective of the study was to evaluate risk factors
for events that occurred in long-term support for out-
patients, events that took place in the immediate perioper-
ative period and during the initial hospital stay were not
evaluated and will be the subject of a separate analysis.
Furthermore, only pre-operative risk factors were considered
in this review. Post-operative factors such as anticoagulation
management, pump parameters, and other acquired risk
factors were not evaluated in this study, but are also the
subject of another analysis currently underway.
Conclusions
Pre-operative factors related to the risk of bleeding, stroke,
and pump thrombosis after initial hospital discharge were
evaluated in a large cohort of advanced heart failure patients
receiving the HMII LVAD as a BTT or DT. Risks of
events were found to differ between demographic groups.
Older age, female, ischemic etiology, and low pre-operative
hematocrit levels were the multivariable risk factors for
bleeding, whereas younger age and female were multivari-
able risk factors for hemorrhagic strokes. Female and a
history of diabetes were the multivariable risk factors for
ischemic stroke, whereas female and higher BMI were the
multivariable risk factors for pump thrombosis. Further
prospective studies are needed to determine whether atargeted anticoagulation management regimen would be
beneﬁcial in the subgroups of patients identiﬁed to be at
high risk of the development of long-term bleeding, stroke,
and thrombosis.
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